2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimates
2009
New biologics for psoriasis and psoriatic arthritis
Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatologic Therapy 2009, 22: 56-60. PMID: 19222517, DOI: 10.1111/j.1529-8019.2008.01216.x.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalArthritis, PsoriaticBiological ProductsClinical Trials as TopicDrug Delivery SystemsHumansPrevalencePsoriasisTumor Necrosis Factor-alphaConceptsPsoriatic arthritisPhase II studyNew biologic therapiesPrevalence of psoriasisSymptoms of psoriasisAlpha monoclonal antibodyTumor necrosis factorHuman tumor necrosis factorCertolizumab pegolBiologic therapyII studyJoint destructionInterleukin-23Rheumatoid arthritisInterleukin-12Radiographic evaluationTreatment optionsAlpha antibodyClinical trialsNecrosis factorNew biologicsArthritisPsoriasisMonoclonal antibodiesAntibodies